COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01017185
Recruitment Status : Completed
First Posted : November 20, 2009
Last Update Posted : May 23, 2019
Information provided by (Responsible Party):
Takara Bio Inc.

Brief Summary:
The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.

Condition or disease Intervention/treatment Phase
Refractory Head and Neck Cancer Squamous Cell Carcinoma, Skin Carcinoma of the Breast Malignant Melanoma Drug: HF10 Phase 1

Detailed Description:

This is an open label, non-randomized, multicenter, two-stage, dose escalation Phase I study evaluating single and repeated intratumoral injections of the oncolytic virus, HF10, in patients with refractory head and neck cancer, or solid tumors with cutaneous and/or superficial lesions (e.g., squamous cell carcinoma of the skin, carcinoma of the breast, and malignant melanoma).

Stage 1: Stage 1 of the study will investigate dose escalation of a single intratumoral injection over the following dose levels: 1 x 10^5 TCID50, 3 x 10^5 TCID50, 1 x 10^6 TCID50, and 1 x 10^7 TCID50. In Stage 1, it is planned that 3 patients will be enrolled per single dose cohort. Within each single dose cohort, accrual will temporarily be suspended after the first patient is entered and the patient will be followed for safety and for viral distribution and elimination. The patients in Stage 1 must be seropositive for HSV-1.

Stage 2: Stage 2 will evaluate repeated intratumoral injections of HF10 at dose levels of 1 x 10^6 TCID50/dose and 1 x 10^7 TCID50/dose. Three patients will be enrolled in each of the repeated dose cohorts. In Stage 2, the first patient treated in each repeated dose cohort must be seropositive for HSV-1. Patients in the repeated dose cohort will receive a total of four intratumoral injections in the same lesion.

Following completion of dosing in the repeated dose cohorts, an expansion cohort of three additional patients will be treated at the highest tolerated dose level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Study Start Date : August 2009
Actual Primary Completion Date : May 2014
Actual Study Completion Date : March 2015

Arm Intervention/treatment
Experimental: Oncolytic virotherapy, intratumoral injection of HF10 Drug: HF10

Primary Outcome Measures :
  1. Assessment of the local tumor response of the HF10-injected tumor by a modified target Response Evaluation Criteria In Solid Tumors (RECIST) method [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Adverse events, vital signs, electrocardiogram(ECG), clinical laboratory tests, and physical exercise [ Time Frame: one year ]
  2. Histological tumor response by biopsy [ Time Frame: one year ]
  3. Overall tumor response of the HF10-injected tumor plus additional non-injected target tumors. [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy, or endocrine therapy) and for which no curative options exist, including, but not limited to:

    • Squamous cell carcinoma of the head and neck
    • Squamous cell carcinoma of the skin
    • Carcinoma of the breast
    • Malignant melanoma
  • Patients may have had any kind and number of prior cancer therapies.
  • Patients must have measurable non-visceral lesions that are evaluable by the RECIST method
  • The tumor mass to be treated must be non-visceral and adequate for injection (i.e., more than 2 cm away from major vascular structures) and measurement by RECIST.
  • Patients in Stage 1 must be seropositive for HSV-1.
  • The first patient enrolled into each cohort in Stage 2 must be seropositive for HSV-1.
  • Patients must be ≥ 18 years of age.
  • Patients must have a life expectancy ≥ 12 weeks
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  • Patients must have adequate hepatic function, as defined as

    • Total bilirubin levels ≤ 1.5 x upper limit of normal (ULN)
    • AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
  • Patients must have adequate renal function as defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine > 1.5 x ULN
  • Patients must have adequate bone marrow function, as defined as

    • Absolute neutrophil count ≥ 1,500/μL and
    • Platelet count ≥ 100,000/μL
  • Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
  • Men and women of childbearing potential must agree to use adequate contraception prior to study entry and for up to six months.
  • Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
  • Patients must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

  • Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or adverse events > Grade 1, except alopecia, resulting from agents administered more than 4 weeks prior to HF10 injection.
  • Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
  • Patients with nasopharyngeal tumors.
  • Patients with deep (below the platysma muscle layer) ulcerative tumors.
  • Patients with target tumors that could potentially invade a major vascular structure(s) (e.g., innominate artery, carotid artery), based on unequivocal imaging findings, as determined by a radiologist.
  • Patients with Grade ≥ 1 pre-existing neurologic abnormalities (CTCAE version 3.0).
  • Patients who have been hospitalized for emergent conditions requiring inpatient evaluation, treatment or procedure during the 30 days prior to entry on study. In addition, emergent conditions requiring inpatient evaluation, treatment or procedure must have resolved or be medically stable and not severe for 30 days prior to entry on study.
  • Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection. Patients will be tested for HIV during pre-treatment screening.
  • Patients receiving steroids or immunosuppressive agents, e.g., for rheumatoid arthritis
  • Concurrent use of any other investigational agents.
  • Presence or history of central nervous system metastasis.
  • Pregnant or breastfeeding women;women desiring to become pregnant within the timeframe of the study are also excluded.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01017185

Layout table for location information
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461-2374
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75230
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Takara Bio Inc.
Layout table for investigator information
Principal Investigator: Robert L Ferris, MD, PhD Division of Head and Neck Cancer Surgery, University of Pittsburgh Cancer Institute
Layout table for additonal information
Responsible Party: Takara Bio Inc. Identifier: NCT01017185    
Other Study ID Numbers: M06-10083
First Posted: November 20, 2009    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Breast Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site
Breast Diseases
Skin Diseases